Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline

AIDS

Volumn 27, Issue 6, 2013, Pages 879-887

  Asahchop, Eugene L ^a,b   Wainberg, Mark A ^a   Oliveira, Maureen ^a   Xu, Hongtao ^a   Brenner, Bluma G ^a   Moisi, Daniela ^a   Ibanescu, Ilinca R ^a   Tremblay, Cecile ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

Antiviral activity; Cross resistance; Etravirine; Replication capacity; Rilpivirine; Second generation nonnucleoside reverse transcriptase inhibitor

Indexed keywords

DAPIVIRINE; EFAVIRENZ; ETRAVIRINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; TENOFOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MONONUCLEAR CELL; MUTAGENESIS; MUTATION; PHENOTYPE; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; VIRUS REPLICATION; WILD TYPE;

ANTI-HIV AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; NITRILES; PYRIDAZINES; PYRIMIDINES; SELECTION, GENETIC; SERIAL PASSAGE; VIRUS REPLICATION;

EID: 84876410269     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835d9f6d     Document Type: Article

References (45)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Richman DD. HIV chemotherapy. Nature 2001; 410:995-1001.
3. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095- 2106.
4. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. AIDS Info. Adolescents PoAGfAa. http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf.January2011.
5. Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, et al. Efficacy and safety of etravirine at week 96 in treatmentexperienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010; 15:1045-1052.
6. Nolan S, Milloy MJ, Zhang R, Kerr T, Hogg RS, Montaner JS, et al. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care 2011; 23:980-987.
7. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242:1168-1171.
8. Aghokeng AF, Vergne L, Mpoudi-Ngole E, Mbangue M, Deoudje N, Mokondji E, et al. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther 2009; 14:401-411.
9. Hurt CB, McCoy SI, Kuruc J, Nelson JA, Kerkau M, Fiscus S, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009; 14:673-678.
10. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002; 18:835-838.
11. Llibre JM, Santos JR, Puig T, Molto J, Ruiz L, Paredes R, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 2008; 62:909-913.
12. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance.N Engl J Med 2011; 365:637-646.
13. Ma L, Huang J, Xing H, Yuan L, Yu X, Sun J, et al. Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces. AIDS Res Hum Retroviruses 2010; 26:1007-1013.
14. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79:12773-12782.
15. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680- 4686.
16. Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47:2550-2560.
17. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet 2007; 370:39-48.
18. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 2010; 24:503-514.
19. Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011; 58:18-22.
20. Lansdon EB, Brendza KM, Hung M, Wang R, Mukund S, Jin D, et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem 2010; 53:4295-4299.
21. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238-246.
22. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, noninferiority trial. Lancet 2011; 378:229-237.
23. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54:718-727.
24. Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni T, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 2011; 55:600-607.
25. Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg- Petersen M, Matee MI, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009; 9:108.
26. Neogi U, Shet A, Shamsundar R, Ekstrand ML. Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine crossresistance. AIDS 2011; 25:1123-1126.
27. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2', 3'-dideoxyinosine and 2', 3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2', 3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1993; 37:1390-1392.
28. Oliveira M, Brenner BG, Wainberg MA. Isolation of drugresistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol 2009; 485:427-433.
29. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46:2087- 2094.
30. Petrella M, Oliveira M, Moisi D, Detorio M, Brenner BG, Wainberg MA. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob Agents Chemother 2004; 48:4189-4194.
31. Haddad M, Napolitano L, Paquet A, Evans M, Petropoulos C, Whitcomb J, Huang W. Mutation Y188L of HIV-1 reverse transcriptase is strongly associated with reduced susceptibility to rilpivirine. In: CROI Seattle, WA, USA, 2012.
32. Winters B, Van Craenenbroeck E, Van der Borght K, Lecocq P, Villacian J, Bacheler L. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J Virol Methods 2009; 162:101-108.
33. Xu HT, Quan Y, Schader SM, Oliveira M, Bar-Magen T, Wainberg MA. The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity. Antimicrob Agents Chemother 2010; 54:2401-2408.
34. Lai MT, Lu M, Felock PJ, Hrin RC, Wang YJ, Yan Y, et al. Distinct mutation pathways of nonsubtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2010; 54:4812-4824.
35. Ren J, Chamberlain PP, Stamp A, Short SA, Weaver KL, Romines KR, et al. Structural basis for the improved drug resistance profile of new generation benzophenone nonnucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem 2008; 51:5000- 5008.
36. Xu HT, Oliveira M, Quashie PK, McCallum M, Han Y, Quan Y, et al. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase. J Virol 2012; 86:8422- 8431.
37. Inouye P, Cherry E, Hsu M, Zolla-Pazner S, Wainberg MA. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1998; 14:735- 740.
38. Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Izopet J, Delaugerre C, et al. Emerging mutations and associated factors in patients displaying treatment failure on an etravirinecontaining regimen. Antivir Ther 2012; 17:119-123.
39. Schader SM, Oliveira M, Ibanescu RI, Moisi D, Colby- Germinario SP, Wainberg MA. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrob Agents Chemother 2012; 56:751-756.
40. Tambuyzer L, Vingerhoets J, Azijn H, Daems B, Nijs S, de Bethune MP, et al. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res Hum Retroviruses 2010; 26:1197-1205.
41. Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A 2008; 105:1466-1471.
42. Poveda E, Garrido C, de Mendoza C, Corral A, Cobo J, Gonzalez- Lahoz J, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of nonnucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 60:1409-1410.
43. Lapadula G, Calabresi A, Castelnuovo F, Costarelli S, Quiros- Roldan E, Paraninfo G, et al. Prevalence and risk factors for etravirine resistance among patients failing on nonnucleoside reverse transcriptase inhibitors. Antivir Ther 2008; 13:601- 605.
44. Kekitiinwa A, Friedman D, Coakley E, Lie Y, Granziano F. Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI-inclusive regimen as first-line ART. Abstr. # 891. In: CROI, San Francisco, CA, USA, 2010.
45. Kiertiburanakul S, Wiboonchutikul S, Sukasem C, Chantratita W, Sungkanuparph S. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. J Clin Virol 2010; 47:330-334.